Akzo's Asenapine
Matches Zyprexa in Mania Study
(October 17, 2007) -- LONDON, (Reuters) - An experimental drug likely to
be acquired by Schering-Plough has a similar power to control mania as the
current "gold standard" treatment, researchers said on Wednesday.
Asenapine was developed by Akzo Nobel's Organon drugs unit, which is
being bought by Schering-Plough.
Clinical trial results presented at the European College of
Neuropsychopharmacology Congress showed the new drug was comparable to Eli
Lilly's
Zyprexa in reducing
mania symptoms in patients with a manic or
mixed episode of
bipolar disorder.
Another study at the meeting also showed asenapine had little effect on
heart rhythm changes in
schizophrenia patients.
Asenapine is considered one of the most important compounds being
developed by Organon, which Schering-Plough agreed to buy in March for 11
billion euros ($15.60 billion) to expand its line of prescription drugs. The
deal is expected to close by the year end.
Some analysts, however, are uncertain about the commercial potential of
the product because Pfizer last year ended a collaboration on the medicine,
following clinical data that did not appear to give it a clear lead over
existing products.
Akzo and
Schering-Plough still believe the drug can be a significant seller, since
the complex nature of bipolar disorder means there is a demand for new
treatment options.
Source: Reuters
Last updated: 10/07
Related Information:
back to
top ~ bipolar news index~
send page to a
friend |